Company intelligence / Profile preview

OliPass Corporation

Ownership: Private
Development stage: Other

Overview

OliPass Corporation develops next-generation RNA therapeutics using its proprietary PNA platform technology. The company's approach centers on inducing exon skipping via cell-permeable PNAs, enabling discovery of multiple new drug candidates. While it has an expanding pipeline targeting various disease genes, most programs appear to be at preclinical or early clinical stages. The company aims for global impact through partnerships and collaborations with pharmaceutical companies.

Therapeutic areas: Other
Modalities: Peptide Nucleic Acid (PNA)-based therapeuticsRNA therapeuticsExon skipping agents
Industry: Biotech

Drug pipeline

8 assets

OLP-1002

7 more assets in the full pipeline.

Partnerships

Plans active collaboration with pharmaceutical and biotech companies for co-development of OPNA-based drugs, but no named partners listed yet.

Beyond the preview

Go deeper on OliPass Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OliPass Corporation.